Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …

Background: The aim of this open label phase II study (NCT00407459) was to assess the
activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined …

Background Few treatment options exist for second-line treatment of malignant pleural
mesothelioma. We aimed to assess the antibody–drug conjugate anetumab ravtansine …

Background There is a preclinical rationale for inhibiting angiogenesis in mesothelioma. We
aimed to assess the efficacy and safety of the anti-VEGFR-2 antibody ramucirumab …

BACKGROUND. We conducted a phase 2, multicenter, open‐label study of erlotinib plus
bevacizumab in patients with malignant pleural mesothelioma who had previously received …

Objectives Pemetrexed-cisplatin is the only FDA-approved regimen for malignant pleural
mesothelioma (MPM), and the impact on survival is modest. No drugs have been shown to …

Introduction Previously published results from a randomized phase III study of pemetrexed
plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a …

Introduction Pemetrexed has established efficacy, and is the backbone for chemotherapy in
patients with malignant pleural mesothelioma (MPM). An International Expanded Access …

Malignant pleural mesothelioma is a rare cancer that is typically associated with exposure to
asbestos. Patients with malignant pleural mesothelioma have poor outcomes with …

Background Nintedanib targets VEGF receptors 1–3, PDGF receptors α and β, FGF
receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural …